Baird analyst David Rescott raised the firm’s price target on Medtronic (MDT) to $96 from $94 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results where PFA upside offset oher downsides on MSD growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $98 from $97 at Bernstein
- Medtronic’s Strong Financial Performance and Positive Outlook Justify Buy Rating
- Medtronic price target raised to $100 from $98 at Wells Fargo
- Positive Outlook for Medtronic Amid Strategic Changes and Elliott Management Investment
- Medtronic Reports Strong Q1 FY26 Results